12 resultaten
PRIORITY TO RELATED APPLICATIONS
This application claims the benefit of European Application No. 05101324.1, filed Feb. 22, 2005, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Substance P is a naturally occurring undecapeptide belonging to the tachykinin
This application is a national stage entry under 35 U.S.C. .sctn. 371 of PCT/IB05/002711, filed Aug. 12, 2005 which claims benefit of Provisional Application No. 60/616,601, filed Oct. 5, 2004.
This invention relates to novel compounds useful in therapy and to processes for the preparation thereof.
This invention relates to novel compounds useful in therapy and to processes for the preparation of such compounds. It also relates to compositions containing such compounds, their use and intermediates used in their preparation.
WO 01/87855 discloses triazole derivatives as inhibitors of glycine
DETAILED DESCRIPTION OF THE INVENTION
The invention relates to novel N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloylamino)-piperidin- es of the formula
##STR00002## wherein Y is .dbd.N-- or .dbd.N(O)--, R is OH when Y is .dbd.N-- and R is H when Y is .dbd.N(O)-- and the ring A is
BACKGROUND
The mammalian neurokinins comprise a class of peptide neurotransmitters which are found in the peripheral and central nervous systems. The three principal neurokinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB).
There are also N-terminally extended forms of at least
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
FIELD OF INVENTION
The invention relates to a compound of formula ##STR1##
wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance